Market News / Story
Medincell (MEDCL) Wins FDA Approval Triggering Royalties, Milestones
·
Medincell said the FDA approved partner Teva’s WELTRUZA, the second drug using its LAI tech. Medincell is due a $4M payment on approval, mid- to high-single digit royalties, and up to $105M in sales-based milestones. Material Details #DetailAI Analyst View1FDA approves WELTRUZARegulatory clearance enables U.S. launch and revenue flow from royalties and milestones.2$4M approval milestone dueImmediate cash inflow; de-risks near-term liquidity.3Royalties mid- to…